Two new triterpenoid saponins, named isoescins IIIa (1) and IIIb (2) were isolated from the seeds of Aesculus chinensis and identified by spectroscopic analysis and chemical hydrolysis. Their structures were establish...Two new triterpenoid saponins, named isoescins IIIa (1) and IIIb (2) were isolated from the seeds of Aesculus chinensis and identified by spectroscopic analysis and chemical hydrolysis. Their structures were established as 21 beta-tigloyl-28-acetylbarringtogenol C-3 beta-O-[beta D-galactopyranosyl( 1-->2)] [beta-D-glucopyranosyl (1-->])1-beta-D-glucopyranosiduronic acid (1) and 21 beta-angeloyl-28-acetylbarringtogenol C-3 beta-O-[beta-D;galactopyranosyl (1-->2)] [beta-D-glucopyranosyl(1 -->4)]-beta-D-glucopyranosiduronic acid (2), which are geometrically isomeric.展开更多
Mucopolysaccharidoses typeⅢB is a rare genetic disorder caused by mutations in the gene that encodes for N-acetyl-alpha-glucosaminidase.This results in the aggregation of heparan sulfate polysaccharides within cell l...Mucopolysaccharidoses typeⅢB is a rare genetic disorder caused by mutations in the gene that encodes for N-acetyl-alpha-glucosaminidase.This results in the aggregation of heparan sulfate polysaccharides within cell lysosomes that leads to progressive and severe debilitating neurological dysfunction.Current treatment options are expensive,limited,and presently there are no approved cures for mucopolysaccharidoses typeⅢB.Adeno-associated virus gene therapy has significantly advanced the field forward,allowing researchers to successfully design,enhance,and improve potential cures.Our group recently published an effective treatment using a codon-optimized triple mutant adeno-associated virus 8 vector that restores N-acetyl-alpha-glucosaminidase levels,auditory function,and lifespan in the murine model for mucopolysaccharidoses typeⅢB to that seen in healthy mice.Here,we review the current state of the field in relation to the capsid landscape,adeno-associated virus gene therapy and its successes and challenges in the clinic,and how novel adenoassociated virus capsid designs have evolved research in the mucopolysaccharidoses typeⅢB field.展开更多
文摘目的观察苗药穴位贴敷治疗IIIB型慢性前列腺炎(chronic prostatitis,CP)的临床疗效及对肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-6(interleukin-6,IL-6)的影响。方法选取2021年6月1日-2022年7月1日贵州中医药大学第二附属医院泌尿男科诊治的湿热瘀滞证IIIB型CP患者60例,随机数表法分为治疗组(苗药穴位贴敷组)和对照组(前列康片组),两组均治疗28 d,治疗结束后采用美国国立卫生研究院CP症状指数(the national institutes of health chronic prostatitis symptom index,NIH-CPSI)评分、中医症状积分及前列腺按摩液中TNF-α、IL-6的水平变化情况,并评估不良反应。结果治疗28 d后,两组NIH-CPSI评分、中医症状积分、细胞因子TNF-α及IL-6水平较治疗前降低(P<0.05),且治疗组低于对照组(P<0.05),治疗组临床显效率高于对照组(χ^(2)=10.335,P<0.01)。结论苗药穴位贴敷可明显改善IIIB型湿热瘀滞证CP患者的NIH-CPSI各项评分、降低中医症状积分、TNF-α及IL-6水平,并且安全性较好,值得进一步深入研究。
文摘Two new triterpenoid saponins, named isoescins IIIa (1) and IIIb (2) were isolated from the seeds of Aesculus chinensis and identified by spectroscopic analysis and chemical hydrolysis. Their structures were established as 21 beta-tigloyl-28-acetylbarringtogenol C-3 beta-O-[beta D-galactopyranosyl( 1-->2)] [beta-D-glucopyranosyl (1-->])1-beta-D-glucopyranosiduronic acid (1) and 21 beta-angeloyl-28-acetylbarringtogenol C-3 beta-O-[beta-D;galactopyranosyl (1-->2)] [beta-D-glucopyranosyl(1 -->4)]-beta-D-glucopyranosiduronic acid (2), which are geometrically isomeric.
文摘Mucopolysaccharidoses typeⅢB is a rare genetic disorder caused by mutations in the gene that encodes for N-acetyl-alpha-glucosaminidase.This results in the aggregation of heparan sulfate polysaccharides within cell lysosomes that leads to progressive and severe debilitating neurological dysfunction.Current treatment options are expensive,limited,and presently there are no approved cures for mucopolysaccharidoses typeⅢB.Adeno-associated virus gene therapy has significantly advanced the field forward,allowing researchers to successfully design,enhance,and improve potential cures.Our group recently published an effective treatment using a codon-optimized triple mutant adeno-associated virus 8 vector that restores N-acetyl-alpha-glucosaminidase levels,auditory function,and lifespan in the murine model for mucopolysaccharidoses typeⅢB to that seen in healthy mice.Here,we review the current state of the field in relation to the capsid landscape,adeno-associated virus gene therapy and its successes and challenges in the clinic,and how novel adenoassociated virus capsid designs have evolved research in the mucopolysaccharidoses typeⅢB field.
